Physician profile
Kenneth E Grant
NPI 1154414225
$3,824.07
in general payments reported to CMS, 2019-2025
22 companies · $2,270 in 2025
The $2,270 reported for 2025 was more than what 87% of Pediatric Gastroenterology providers received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $349 · 2020: $25.14 · 2021: $374 · 2022: $85.19 · 2023: $298 · 2024: $423 · 2025: $2,270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,641 · Food and Beverage: $1,342 · Education: $6.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,641.43 |
| Food and Beverage | $1,342.07 |
| Education | $6.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $2,140.76 | 2021-2025 | Gattex |
| Abbvie INC. | $723.02 | 2019-2024 | |
| Mirum Pharmaceuticals, INC. | $191.73 | 2023-2025 | Livmarli |
| Travere Therapeutics, INC. | $105.26 | 2019-2023 | Cholbam |
| Janssen Biotech, INC. | $99.73 | 2024-2025 | Tremfya |
| Alcresta Therapeutics, INC. | $66.56 | 2023-2025 | Relizorb |
| Ironwood Pharmaceuticals, INC | $62.23 | 2023 | Linzess |
| Fresenius Kabi USA, LLC | $55.73 | 2023 | Idacio |
| Albireo Pharma, INC. | $49.63 | 2024 | Bylvay |
| Nestle Healthcare Nutrition INC. | $45.70 | 2021-2022 | |
| Ucb, INC. | $44.94 | 2022 | |
| Sandoz INC. | $39.36 | 2024 | Hyrimoz |
| Qol Medical, LLC | $32.78 | 2024 | Sucraid |
| Ascendis Pharma Endocrinology INC | $24.72 | 2025 | Skytrofa |
| Tandem Diabetes Care, INC. | $23.64 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $22.74 | 2024 | Zymfentra |
| Rhythm Pharmaceuticals, INC. | $20.67 | 2025 | Imcivree |
| Zogenix INC. | $19.84 | 2021 | |
| Covidien Lp | $16.25 | 2019 | |
| Concordia Pharmaceuticals INC. | $13.23 | 2019 | |
| Glaxosmithkline, LLC. | $12.86 | 2023 | Nucala |
| Cumberland Pharmaceuticals, INC. | $12.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Grant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.